NCT03383094View on ClinicalTrials.gov

Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

March 15, 2018

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Head and Neck Squamous Cell CarcinomaCancerCancer of Head and NeckCancer, AdvancedCancer, MetastaticTumorTumor RecurrenceTumor NeckTumor MetastasisOral CancerOropharyngeal CancerOropharynx CancerOropharynx Cancer, Stage IIIOropharynx Cancer, RecurrentOropharynx Cancer, Metastatic
Interventions
DRUG

Pembrolizumab

Pembrolizumab 200 mg IV infusion every 3 weeks x 20 cycles

RADIATION

Radiation therapy

70 Gy in 33-35 fractions

DRUG

Cisplatin

100 mg/m2 Weeks 1, 4, and 7.

Trial Locations (6)

33612

H. Lee Moffitt Cancer Center & Research Facility, Tampa

37203

Vanderbilt-Ingram Cancer Center, Nashville

45219

University of Cincinnati Medical Center, Cincinnati

63110

Washington University School of Medicine, Siteman Cancer Center, St Louis

85719

University of Arizona Cancer Center, Tucson

92093

UC San Diego Moores Cancer Center, La Jolla

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Loren Mell, MD

OTHER